AUTHOR'S VIEW OPEN Spotlight on systems vaccinology: a novel approach to elucidate correlates of protection

Henderson Zhu^{1,2}, Irina Chelysheva (b^{1,2}, Andrew J. Pollard (b^{1,2} and Daniel O'Connor (b^{1,2})

© The Author(s) 2023

Genes & Immunity; https://doi.org/10.1038/s41435-023-00247-2

Systems vaccinology employs multi-omic approaches, including transcriptomics, immunomics, proteomics, and metabolomics to detail the complex alterations in the biological systems of vaccine recipients after vaccination [1, 2]. Within this broad field, our recent article highlights a focused approach [3]. We describe a contemporary workflow, specifically using transcriptomic and immunomic analyses, tDE@Spr!ng19o establish correlates of vaccine-induced protection against typhoid fever (Fig. 1). Typhoid fever, caused by *Salmonella enterica* serovar Typhi (S. Typhi), continues to pose a substantial public health burden in many resource-limited regions of the world, resulting in approximately 100,000 deaths every year [4].

The substantial disease burden coupled with the emergence of antimicrobial resistant typhoid strains highlights the urgent need for effective vaccines to be deployed. Previous vaccines against typhoid fever failed to induce sufficient levels of protection in infants and toddlers. Therefore, there was a pressing need for alternative vaccines for paediatric immunisation. The fact that typhoid fever exclusively affects humans means that there are no non-human animal models for elucidating important features of the immune response to infection (e.g., correlates of protection). However, progress in this field has been accelerated by work of investigators at Oxford University, led by Professor Sir Andrew Pollard, establishing a controlled human infection model (CHIM), which quantified and contrasted vaccine efficacies of a licenced plain polysaccharide and a newer glycoconjugate typhoid vaccine [5].

A pivotal aspect of the current study was the generation of bulk RNA-sequencing data from blood samples collected at defined time points post-vaccination and post-oral typhoid challenge within the CHIM setting. As glycoconjugate vaccines and plain polysaccharide vaccines elicit protection through humoral immunity, coupling transcriptomic analyses with B-cell oriented immunomic analyses provided valuable insights. Transcriptomic analysis revealed that by 7 days post vaccination, recipients of both vaccines exhibited upregulation of humoral immunityrelated genes such as *IGHG1* and *IGHV3-23*. These elevated signatures indicate a robust B-cell clonal expansion at 7 days post vaccination. Thus, quantifying the relative magnitudes of these clonal expansions may provide insight into protection. In agreement with previous findings, most glycoconjugate vaccine recipients who did not develop typhoid fever showed considerably higher levels of clonal expansion when compared with those who developed the disease. This observation enabled a correlation between the level of clonal expansion and protection to be established.

To identify the exact B-cell receptor clonotypes contributing to the clonal expansions seen after vaccination, we developed a high-throughput B-cell receptor (BCR) clonotype clustering method. This enabled the identification of an upregulated BCR cluster commonly seen amongst participants that did not develop typhoid fever post-challenge. This cluster's BCR clonotypes shared sequence homology with antibodies experimentally determined to bind the Vi-capsular polysaccharide of *S*. Typhi. Thus, both computational and experimental evidence point to the protective role of these BCR clonotypes which matured following administration of both the plain polysaccharide vaccine and the glycoconjugate vaccine. This finding confirms a convergent humoral response while also identifying the protective component of the observed humoral response.

We think that immunomic analyses can serve as a complementary approach to other types of transcriptomic analyses for establishing correlates of protection, by elucidating protective B- or T-cell receptor clonotypes. In our study, we demonstrated that the B-cell clonal expansion can be effectively captured by transcriptomic analysis of blood samples taken post-vaccination, revealing novel correlates of vaccine-induced protection.

Received: 29 November 2023 Revised: 4 December 2023 Accepted: 13 December 2023 Published online: 26 December 2023

¹Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK. ²NIHR Oxford Biomedical Research Centre, Oxford, UK. ¹²mil: Daniel.oconnor@paediatrics.ox.ac.uk




Fig. 1 Schematic of the vaccine study and the outputs from the systems vaccinology pipeline.

REFERENCES

- O'Connor D. The omics strategy: the use of systems vaccinology to characterise immune responses to childhood immunisation. Expert Rev Vaccines 2022:1205–14.
- 2. Pulendran B, Li S, Nakaya HI. Systems vaccinology. Immunity. 2010;33:516-29.
- Zhu H, Chelysheva I, Cross DL, Blackwell L, Jin C, Gibani MM, et al. Molecular correlates of vaccine-induced protection against typhoid fever. J Clin Investig. 2023.
- Collaborators GTaP. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis. 2019;19:369–81.
- 5. Jin C, Gibani MM, Moore M, Juel HB, Jones E, Meiring J, et al. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet. 2017;390:2472–80.

AUTHOR CONTRIBUTIONS

All authors contributed equally to this work.

COMPETING INTERESTS

AJP is chair of the UK Department of Health and Social Care's Joint Committee on Vaccination and Immunization and was a member of WHO's SAGE until 2022. The views expressed are those of the authors and not necessarily those of the National Health Service (NHS), the National Institute for Health Research (NIHR), or the UK Department of Health.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to Daniel O'Connor.

Reprints and permission information is available at http://www.nature.com/ reprints

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http:// creativecommons.org/licenses/by/4.0/.

© The Author(s) 2023